Navigation Links
Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2009 Financial Results on November 5, 2009
Date:10/29/2009

SAN DIEGO, Oct. 29 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, today announced that it will release its third quarter ended September 30, 2009 financial results after the market closes on Thursday, November 5, 2009.

Cadence management will host a conference call and live webcast to discuss the financial results on Thursday, November 5, 2009 at 1:30 pm Pacific Time (4:30 pm Eastern Time). Interested investors may participate in the conference call by dialing 888-811-5448 (domestic) or 913-312-4376 (international). To access the webcast, please visit the company's website at www.cadencepharm.com and go to the Investor Relations page. A replay of the webcast will be available approximately two hours after the call and remain available on the company's website until the next quarterly financial results call.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

    Contacts:       William R. LaRue
                    SVP & Chief Financial Officer
                    Cadence Pharmaceuticals, Inc.
                    858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.


'/>"/>
SOURCE Cadence Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
2. Cadence Pharmaceuticals Names Malvina Laudicina Vice President of Regulatory Affairs and Quality Assurance
3. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at UBS 2007 Global Life Sciences Conference
4. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIO Investor Forum
5. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at BIOCOM Investor Conference 2007
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Third Quarter 2007 Financial Results
7. Cadence Pharmaceuticals CEO Theodore Schroeder to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference on February 5, 2008 in New York
8. Cadence Pharmaceuticals to Raise up to $49.3 Million in Registered Direct Common Stock Offering
9. Cadence Pharmaceuticals Completes $49.3 Million Registered Direct Offering
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Cadence Pharmaceuticals to Present at the Cowen and Company 28th Annual Health Care Conference on March 20, 2008 in Boston

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)... , SEATTLE, Nov. 20 /PRNewswire-FirstCall/ ...CTIC) announced today that the Ninth Circuit Court...nd ruled that CTI should be allowed to pursue all ...case back to the District Court for trial. CTI fi...er third-party reimbursement consultant for CTI,s ...
(Date:11/19/2009)... , SEATTLE, Nov. 19 O... unaudited financial results for the third quarter...ded September 30, 2009, Omeros reported a net loss...to a net loss of $7.4 million, or $2.54 per share,...ended September 30, 2009, the Company reported a n...
(Date:11/19/2009)... , MALVERN, Pa. and WALTHAM, Mass., Nov. 19... and Decision Resources find that the leading driv... in Europe is broad-spectrum activity against gram...variety of organisms that can cause nosocomial pne...hey look primarily for agents that provide appropr...
(Date:11/19/2009)... InSound is honored by latest ... Newark, CA (PRWEB) November 16, 2009...ldquo;invisible” hearing aid from InSound Me... New Award in the Health category.  &nbs...s designed to reside deep in the hearing canal for...
Breaking Biology Technology:Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 2Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 3Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 4Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 5Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 6Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 7Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights 8Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 2Broad-Spectrum Antibacterial Activity is the Most Important Driver of Antibiotic Selection for Nosocomial Pneumonia In Europe 3Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 2Popular Science Awards Lyric “Invisible” Hearing Aid 2009 “Best of What's New” Award 3
...: Its more than concentration , Be sure... valid comparison. SPEX conservatively quotes a ...the FluoroMax . In 2001, the average FluoroMax ...ipped with a S/N below 3000:1. Compare this to oth... compare experimental conditions. SPEX calculate...
...n , The brightly-colored coral reefs th...hen vacationers stay in the Caribbean or South Pac... of fish and underwater life. Not only do the reef...larger predators, but also some fish actually surv...otection to plants and animals from the ravages of...
..., , Simultaneously monitoring the...s is necessary to properly assess the effectivenes...ofluorometer allows the user to monitor up to eigh...lengths. Coupling this capability with the proper ...ng biological processes. , , Res...
Other Biology Technology:How to select the best spectrofluorometer 2Fluorescent pigments in living coral 2Fluorescent pigments in living coral 3
(Date:11/19/2009)...the genetic instructions inside corn, one of the b...the most complex sequences of DNA ever analyzed, s...id Schwartz, who was one of more than 100 authors ...maize genome is a true maze full of confusing rep...uencers for years," says Schwartz. , Publication...
(Date:11/19/2009)...he offspring of two inbred strains tend to be supe...gene-level variability that leads to this phenomen...t our ability to custom-tailor crops for specific ...sumption or high glucose content for biomass fuel....ce of the common corn strain B73, University of Mi...
(Date:11/19/2009)...aize, also known as corn, researchers across the U...d pave the way to significant improvements in a pl...eed and fiber around the world. , The new map, a..., charts genetic diversity and recombination acros...arch team, led by U.S. Department of Agriculture s...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3U of M plant scientist uncovers clues to yield-boosting quirks of corn genome 2Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 1Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 2Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 3Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 4Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 5Palatin Technologies Inc Reports First Quarter Fiscal Year 2010 Results 3B Teleconference and Webcast to be held on November 16 2009 14847 6Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference 14843 1Cornerstone Therapeutics to Present at the 6th Annual Lazard Capital Markets Healthcare Conference 14843 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 1Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 2Sleep Management Device Unit Sales to Grow at a Compound Annual Growth Rate of Over 16 25 as CMS Reimbursement Expands 6280 3
...odel, a correlation-based statistical method is a ... and pinpoint genes that may be potential cancer t...y research. , The research is important because i... gene connections, a task critical for understandi... appeared this week in the online edition of the P...
...heart attack have long been treated with morphine ...from the Duke Clinical Research Institute has show...her risk of dying. , The researchers call for a r.... Meanwhile, they advise cardiologists to begin tr...relieve pain before resorting to morphine. , In th...
... researchers at the Huntsman Cancer Institute at t...a mutant gene found in up to 30 percent of human t...e important in cell signaling, or communication am...ene" or cancer-causing gene that has been shown to...lon and lung, as well as thyroid cancer and leukem...
Other Biology News:Researchers develop promising new gene network analysis method 2Morphine for Chest Pain Increases Death Risk 2Morphine for Chest Pain Increases Death Risk 3Scientists inhibit cancer gene 2
Sheep Anti-11-DEOXY-CORTICOSTERONE (-OCMO) Polyclonal Antibody, Unconjugated from AbD Serotec
Equine Immunoglobulin G from Equitech-Bio
Mouse Anti-Human IFN-Gamma RC2 (CD118) Non-Neutralizing Monoclonal Antibody, Unconjugated, Clone MMHGR-2 from PBL InterferonSource
Rat CINC-2 beta, Unconjugated from R&D Systems
Biology Products: